ACAD stock


ACADIA Pharmaceuticals Inc. (ACAD) Gets a Price Target Jump; Here’s Why

One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.

ACADIA Pharmaceuticals Inc. (ACAD) 3Q:17 Net Sales Grew to $35.6 Million

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the third quarter ended September 30, 2017.

ACADIA Pharmaceuticals Inc.’s (ACAD) Phase II Study in Alzheimer’s Disease Psychosis Faces Criticism; Top Analyst Weighs In

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) tumbled nearly 9% in Monday’s trading session, after the drug maker announced the presentation of data from the …

ACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with Severe Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer’s disease psychosis at the …

ACADIA Pharmaceuticals Inc. (ACAD) Hits New 52-Week High Following Breakthrough Therapy Designation; J.P. Morgan Weighs In

ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.

Here’s Why ACADIA Pharmaceuticals Inc. (ACAD) Shares Popped

Investors are pricing in some optimism in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker announced that the FDA has granted Breakthrough Therapy Designation to …